Patents Examined by Brad Duffy
  • Patent number: 11447557
    Abstract: The present disclosure provides multispecific (e.g., bispecific) antibodies that specifically bind to human GITR and/or human OX40 as well as compositions comprising such antibodies. In a specific aspect, the multispecific antibodies specifically bind to human GITR and OX40 and modulate GITR and/or OX40 activity, e.g., enhance, activate, or induce GITR and/or OX40 activity, or reduce, deactivate, or inhibit GITR and/or OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., enhances, activates, or induces GITR and/or OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., reduces, deactivates, or inhibits GITR and/or OX40 activity.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: September 20, 2022
    Assignees: Agenus Inc., Memorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research Ltd.
    Inventors: Nicholas S. Wilson, Jeremy D. Waight, Gerd Ritter, David Schaer, Daniel Hirschhorn-Cymerman, Taha Merghoub, Ekaterina V. Breous-Nystrom, Volker Seibert, Takemasa Tsuji, Olivier Léger, Dennis J. Underwood, Marc Van Dijk
  • Patent number: 11447561
    Abstract: The present disclosure describes antibodies including caninized antibodies against canine PD-L1 with specific properties. The document relates to epitopes of canine PD-L that bind to these antibodies, as well as to anti-canine PD-L1 antibodies that bind these epitopes, and to the use of the caninized anti-canine PD-L1 antibodies in the treatment of cancer in dogs.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: September 20, 2022
    Assignee: Intervet, Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey
  • Patent number: 11447573
    Abstract: Disclosed herein are multispecific, such as bispecific, antigen binding proteins comprising a first antigen binding domain comprising a heavy chain variable domain and a light chain variable domain, and a second antigen binding domain comprising a single-domain antibody. Pharmaceutical compositions comprising the multispecific antigen binding proteins, kits and methods of use thereof are further provided.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: September 20, 2022
    Assignee: NANJING LEGEND BIOTECH CO., LTD.
    Inventors: Chuan-Chu Chou, Yafeng Zhang, Shu Wu, Zhenyu Liu, Zhongdao Li, Fangliang Zhang
  • Patent number: 11447567
    Abstract: The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human FLT3 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: September 20, 2022
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Tobias Raum, Claudia Blümel, Franziska Bott, Christoph Dahlhoff, Patrick Hoffmann, Elisabeth Nahrwold, Jochen Pendzialek
  • Patent number: 11427650
    Abstract: The present invention provides dual specificity antibody fusion proteins comprising an antibody Fab or Fab? fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody which has specificity for a second antigen of interest.
    Type: Grant
    Filed: January 21, 2019
    Date of Patent: August 30, 2022
    Assignee: UCB BIOPHARMA SRL
    Inventors: David Paul Humphreys, Emma Dave, Laura Griffin, Sam Philip Heywood
  • Patent number: 11426452
    Abstract: The disclosure relates to polypeptides and pharmaceutical compositions comprising polypeptides that find use in the prevention or treatment of cancer, in particular breast cancer, ovarian cancer and colorectal cancer. The disclosure also relates to methods of inducing a cytotoxic T cell response in a subject or treating cancer by administering pharmaceutical compositions comprising the peptides, and companion diagnostic methods of identifying subjects for treatment. The peptides comprise T cell epitopes that are immunogenic in a high percentage of patients.
    Type: Grant
    Filed: December 22, 2021
    Date of Patent: August 30, 2022
    Assignee: Treos Bio Limited
    Inventors: Julianna Lisziewicz, Levente Molnár, Eniko R. Toke, József Toth, Orsolya Lorincz, Zsolt Csiszovszki, Eszter Somogyi, Katalin Pántya, Mónika Megyesi
  • Patent number: 11419948
    Abstract: Ultra-low crosslinked microgels made of an ultra-low crosslinked polymer are provided. The microgels, also referred to as Platelet-like Particles (PLPs), preferably have <0.5% crosslinking densities. One or more of the polymers are conjugated with a fibrin-binding element or moiety, preferably H6, in an amount effective to confer to the microgel selective binding to fibrin under physiological conditions. The PLPs can recapitulate multiple key functions of platelets including binding, stabilizing and enhancing fibrin clot formation, responsiveness to injury cues, and induction of clot contraction. In a preferred embodiment, the microgel or PLP has little or no binding to soluble fibrinogen under physiological conditions compared to its binding to fibrin. The microgels or PLPs are prepared using crosslinker-free synthesis conditions, and can promote or induce clotting and clot contraction.
    Type: Grant
    Filed: February 4, 2019
    Date of Patent: August 23, 2022
    Assignees: Georgia Tech Research Corporation, University of Virginia Patent Foundation, North Carolina State University
    Inventors: Thomas H. Barker, Ashley Carson Brown, Louis Andrew Lyon, Sarah E. Stabenfeldt, Nicole Welsch, John Nicosia
  • Patent number: 11401342
    Abstract: The invention relates to improved binding molecules that bind specifically to prostate specific membrane antigen (PSMA), in particular, single human variable heavy chain domain antibodies and related methods for treatment of cancer.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: August 2, 2022
    Assignee: CRESCENDO BIOLOGICS LIMITED
    Inventors: Nikki Royle, Steve Vance, Viviane Zelenay
  • Patent number: 11401343
    Abstract: The present invention relates to an anti-MSLN antibody and a pharmaceutical composition for cancer treatment comprising same. The anti-MSLN antibody according to the present invention has high affinity and specificity for MSLN and thus can be effectively used in cancer prevention or treatment.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: August 2, 2022
    Assignees: GREEN CROSS CORPORATION, MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Ki Su Kim, Jung Hong Jeong, Dong Sik Kim, Yang Mi Lim, Yong Yea Park, Hyung Kwon Lim, Jong Wha Won
  • Patent number: 11396555
    Abstract: Provided is a monoclonal antibody which specifically recognizes B cell lymphoma cells and a use thereof. More specifically, provided are the monoclonal antibody; a pharmaceutical composition for preventing or treating B cell lymphoma including the monoclonal antibody; a composition for diagnosing B cell lymphoma including the monoclonal antibody; a method for providing information for diagnosing B cell lymphoma using the monoclonal antibody; a chimeric antigen receptor (CAR) protein including i) the antibody, ii) a transmembrane domain, and iii) an intracellular signaling domain; a recombinant vector which expresses the CAR protein; a CAR-modified T cell transformed with the recombinant vector; a pharmaceutical composition for preventing or treating B cell lymphoma including the CAR-modified T cell; and an antibody-drug conjugate wherein the monoclonal antibody and a drug are conjugated.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: July 26, 2022
    Assignee: Eutilex Co., Ltd.
    Inventors: Byoung Se Kwon, Kwang-Hui Kim, Young-Ho Kim, Ho-sik Oh, Don-Gil Lee, Seung-Joo Lee, Beom-Kyu Choi, Insoo Park, Chungyong Han
  • Patent number: 11370842
    Abstract: Provided herein are, inter alia, antibodies capable of binding Interleukin-1 receptor accessory protein (IL1RAP). The antibodies provided herein include novel light chain and heavy chain sequences and bind IL1RAP with high efficiency and specificity. The anti-IL1RAP antibodies provided herein are, inter alia, useful for the treatment of IL1RAP-expressing cancers such as AML.
    Type: Grant
    Filed: August 1, 2018
    Date of Patent: June 28, 2022
    Assignee: CITY OF HOPE
    Inventors: Weixu Meng, Guido Marcucci
  • Patent number: 11365256
    Abstract: The present disclosure relates to immunoglobulins that bind Fc?RIIb+ B cells and coengage CD19 on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins for the treatment of an IgG4-related disease.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: June 21, 2022
    Assignee: XENCOR, INC.
    Inventors: Debra Zack, John H. Stone, Shiv Pillai, Paul Foster
  • Patent number: 11351251
    Abstract: The present invention relates to antibodies that are heterodimeric and bind human PD-L1 and human TIM-3, and may be useful for treating cancer alone and in combination with chemotherapy and other cancer therapeutics.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: June 7, 2022
    Assignees: Eli Lilly and Company, Zymeworks Inc.
    Inventors: Yiwen Li, Dale Lincoln Ludwig, Yang Shen, Yi Zhang, Igor Edmondo Paolo D'Angelo
  • Patent number: 11352439
    Abstract: Modified macrophage immune cells are provided for treatment of cancer and other diseases.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: June 7, 2022
    Inventors: Kim Leslie O'Neill, Scott Weber
  • Patent number: 11345760
    Abstract: The present disclosure relates to a multi-specific antibody molecule comprising or consisting of: a) a polypeptide chain of formula (I): VH—CH1—X—V1; and b) a polypeptide chain of formula (II): VL-CL-Y—V2 and pharmaceutical formulations comprising, for example for use in treatment. The disclosure also provides polynucleotide sequences encoding said multispecific antibody molecules, vectors comprising the polynucleotides and host cells comprising said vectors and/or polynucleotide sequences. There is a provided a method of expressing a multispecific antibody molecule of the present disclosure from a host cell.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: May 31, 2022
    Assignee: UCB BIOPHARMA SRL
    Inventors: Pallavi Bhatta, Emma Dave, Sam Philip Heywood, David Paul Humphreys
  • Patent number: 11332544
    Abstract: Genetically engineered antibodies containing non-native N-glycosylated sites, preparation of the antibodies in yeast and fungi, site-specific conjugation of drugs to these antibodies, and methods of treatment utilizing these antibodies are described herein.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: May 17, 2022
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Robert Davidson, Bing Gong
  • Patent number: 11332533
    Abstract: The present inventors succeeded in improving the antibody constant region to have increased stability under acid conditions, reduced heterogeneity originated from disulfide bonds in the hinge region, reduced heterogeneity originated from the H chain C terminus, and increased stability at high concentrations as well as in discovering novel constant region sequences having reduced Fc? receptor-binding, while minimizing the generation of novel T-cell epitope peptides. As a result, the present inventors successfully discovered antibody constant regions with improved physicochemical properties (stability and homogeneity), immunogenicity, safety, and pharmacokinetics.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: May 17, 2022
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Hirotake Shiraiwa
  • Patent number: 11332539
    Abstract: Provided is a fusion protein comprising a polypeptide component that blocks binding of CD47 to SIRP alpha and a polypeptide that binds to and triggers a TRAIL receptor or Fas. Also provided is a method of treating cancer in a patient comprising administering the fusion protein of the invention to a patient in need of such treatment.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: May 17, 2022
    Assignee: Thomas Jefferson University
    Inventor: Mark L. Tykocinski
  • Patent number: 11331394
    Abstract: This invention, among other things, relates to CD19 binding agents and methods of using such CD binding agents for treating disease.
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: May 17, 2022
    Assignee: SEAGEN INC.
    Inventors: Charlotte McDonagh, Charles G. Cerveny, Dennis Benjamin, Paul Carter
  • Patent number: 11319371
    Abstract: The present invention relates to novel antibodies that are specific for human CD3, in particular for the CD3? domain.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: May 3, 2022
    Assignee: Numab Therapeutics AG
    Inventors: Tea Gunde, Christian Hess, Sebastian Meyer, Alexandre Simonin, Teddy Beltrametti, David Urech